Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases

Jing WANG; Bin TAN; Zhijie ZHAO; Haochen ZHONG; Linlin QU

doi:10.3969/j.issn.1001-5256.2022.02.028

Volume 38 Issue 2

Feb. 2022

Turn off MathJax

Article Contents

Abstract

References

Supplements

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(2): 409-414

PDF( 3577 KB)

Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases

DOI: 10.3969/j.issn.1001-5256.2022.02.028

Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China

Research funding:

Scientific Research Award Fund for Young and Middle-Aged Scientists in Shandong Province (BS2011YY004);

Chen Xiaoping Science and Technology Development Fund of Hubei Province (CXPJJH12000002-2020057);

Li Jieshou Intestinal Barrier Research Foundation of China International Medical Exchange Foundation in 2019 (Z-2017-24-2009)

More Information

Corresponding author: QU Linlin, taxue9455@sina.com
Received Date: 2021-07-07
Accepted Date: 2021-08-26
Published Date: 2022-02-20

Abstract

Abstract

Objective To investigate the gene mutations of Chinese patients with pancreatic cancer in the coastal regions of Eastern China, and to provide a basis for individualized treatment. Methods A total of 40 patients who were admitted and diagnosed with malignant pancreatic tumor after surgical treatment in The Affiliated Hospital of Qingdao University, Qingdao Municipal Hospital, Yantaishan Hospital, and Yantai Sino-France Friendship Hospital from January 2017 to June 2019 were enrolled. Next-generation sequencing (NGS) was used to detect gene mutations in tumor tissue and somatic cells, and the map of gene mutations was plotted to analyze genomic alterations. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to plot survival curves, and the log-rank test was used for comparison between groups. Results Among the 40 patients, 34 (85.0%) had pancreatic ductal adenocarcinoma, 3 (7.5%) had solid pseudopapillary neoplasm of the pancreas, 1 (2.5%) had pancreatic neuroendocrine tumor, and 2 (5.0%) had unclear typing. KRAS (80.0%, 32/40), TP53 (70.0%, 28/40), CDKN2A (32.5%, 13/40), SMAD4 (17.5%, 7/40), and AKT2 (17.5%, 7/40) were the most common mutations, and there was no significant difference in survival time between the patients with these five common gene mutations (all P > 0.05). Conclusion NGS technology can provide comprehensive and accurate information of genomic alterations and may provide novel potential biomarkers for the diagnosis and precise treatment of pancreatic cancer. The analysis of mutant genes also lays a foundation for the individualized treatment of pancreatic cancer.
- Pancreatic Neoplasms,
- Genome,
- Mutation

FullText(HTML)

References(28)

References

[1]	SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551.
[2]	STEUER CE, RAMALINGAM SS. Tumor mutation burden: Leading immunotherapy to the era of precision medicine?[J]. J Clin Oncol, 2018, 36(7): 631-632. DOI: 10.1200/JCO.2017.76.8770.
[3]	von HOFF DD, ERVIN T, ARENA FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18): 1691-1703. DOI: 10.1056/NEJMoa1304369.
[4]	CONROY T, PAILLOT B, FRANÇOIS E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study[J]. J Clin Oncol, 2005, 23(6): 1228-1236. DOI: 10.1200/JCO.2005.06.050.
[5]	FRANCO J, WITKIEWICZ AK, KNUDSEN ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer[J]. Oncotarget, 2014, 5(15): 6512-6525. DOI: 10.18632/oncotarget.2270.
[6]	OSHIMA M, OKANO K, MURAKI S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer[J]. Ann Surg, 2013, 258(2): 336-346. DOI: 10.1097/SLA.0b013e3182827a65.
[7]	BIANKIN AV, WADDELL N, KASSAHN KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes[J]. Nature, 2012, 491(7424): 399-405. DOI: 10.1038/nature11547.
[8]	KAWAGUCHI K, IGARASHI K, MIYAKE K, et al. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model[J]. Tissue Cell, 2018, 52: 124-128. DOI: 10.1016/j.tice.2018.05.003.
[9]	BOURNET B, BUSCAIL C, MUSCARI F, et al. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities[J]. Eur J Cancer, 2016, 54: 75-83. DOI: 10.1016/j.ejca.2015.11.012.
[10]	MORTON JP, TIMPSON P, KARIM SA, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer[J]. Proc Natl Acad Sci U S A, 2010, 107(1): 246-251. DOI: 10.1073/pnas.0908428107.
[11]	Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma[J]. Cancer Cell, 2017, 32(2): 185-203. DOI: 10.1016/j.ccell.2017.07.007.
[12]	WADDELL N, PAJIC M, PATCH AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer[J]. Nature, 2015, 518(7540): 495-501. DOI: 10.1038/nature14169.
[13]	ORMANNS S, HAAS M, REMOLD A, et al. The impact of SMAD4 loss on outcome in patients with advanced pancreatic cancer treated with systemic chemotherapy[J]. Int J Mol Sci, 2017, 18(5): 1094. DOI: 10.3390/ijms18051094.
[14]	XIA X, WU W, HUANG C, et al. SMAD4 and its role in pancreatic cancer[J]. Tumour Biol, 2015, 36(1): 111-119. DOI: 10.1007/s13277-014-2883-z.
[15]	CRANE CH, VARADHACHARY GR, YORDY JS, et al. Phase Ⅱ trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression[J]. J Clin Oncol, 2011, 29(22): 3037-3043. DOI: 10.1200/JCO.2010.33.8038.
[16]	OTTENHOF NA, MORSINK FH, TEN KATE F, et al. Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only[J]. Cell Oncol (Dordr), 2012, 35(2): 119-126. DOI: 10.1007/s13402-012-0072-x.
[17]	SHIN SH, KIM HJ, HWANG DW, et al. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study[J]. Oncotarget, 2017, 8(11): 17945-17959. DOI: 10.18632/oncotarget.14901.
[18]	CHENG JQ, RUGGERI B, KLEIN WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA[J]. Proc Natl Acad Sci U S A, 1996, 93(8): 3636-3641. DOI: 10.1073/pnas.93.8.3636.
[19]	RUGGERI BA, HUANG L, WOOD M, et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas[J]. Mol Carcinog, 1998, 21(2): 81-86.
[20]	CUI Y, WANG Q, WANG J, et al. Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells[J]. Brain Res, 2012, 1469: 1-9. DOI: 10.1016/j.brainres.2012.06.043.
[21]	NITULESCU GM, MARGINA D, JUZENAS P, et al. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)[J]. Int J Oncol, 2016, 48(3): 869-885. DOI: 10.3892/ijo.2015.3306.
[22]	CHEN D, NIU M, JIAO X, et al. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma[J]. Int J Mol Sci, 2012, 13(1): 1186-1208. DOI: 10.3390/ijms13011186.
[23]	LIU Q, TURNER KM, ALFRED YUNG WK, et al. Role of AKT signaling in DNA repair and clinical response to cancer therapy[J]. Neuro Oncol, 2014, 16(10): 1313-1323. DOI: 10.1093/neuonc/nou058.
[24]	KORINEK V, BARKER N, MORIN PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC^-/- colon carcinoma[J]. Science, 1997, 275(5307): 1784-1787. DOI: 10.1126/science.275.5307.1784.
[25]	LOGAN CY, NUSSE R. The Wnt signaling pathway in development and disease[J]. Annu Rev Cell Dev Biol, 2004, 20: 781-810. DOI: 10.1146/annurev.cellbio.20.010403.113126.
[26]	CLEVERS H. Wnt/beta-catenin signaling in development and disease[J]. Cell, 2006, 127(3): 469-480. DOI: 10.1016/j.cell.2006.10.018.
[27]	SINGHI AD, GEORGE B, GREENBOWE JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers[J]. Gastroenterology, 2019, 156(8): 2242-2253. DOI: 10.1053/j.gastro.2019.02.037.
[28]	WEISS GJ, BLAYDORN L, BECK J, et al. Phase Ib/Ⅱ study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma[J]. Invest New Drugs, 2018, 36(1): 96-102. DOI: 10.1007/s10637-017-0525-1.

Relative Articles

[1]	Jiongjiong BI, Yingjie MA. Characteristics of the composition of intestinal flora in cirrhotic patients with malnutrition[J]. Journal of Clinical Hepatology, 2024, 40(1): 83-88. doi: 10.12449/JCH240115
[2]	Nan GENG, Ming KONG, Yu CHEN, Zhongping DUAN. Association between portal hypertension and malnutrition in liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2205-2209. doi: 10.3969/j.issn.1001-5256.2023.09.026
[3]	Honglin MA, Jing YANG, Qiu JIN, Run LUO, Jiao LENG, Xia WANG. Current status of research on nutritional support in end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 215-219. doi: 10.3969/j.issn.1001-5256.2022.01.038
[4]	Yumei HE, Liping WU, Zhiming WANG, Menghao HAO, Ling HU, Jiazhen LI, Xiaobin SUN. Research progress in nutritional support for liver cirrhosis patients[J]. Journal of Clinical Hepatology, 2022, 38(12): 2846-2849. doi: 10.3969/j.issn.1001-5256.2022.12.031
[5]	Yijun ZHANG, Qian ZHANG, Xinhua LUO. Assessment and clinical management of malnutrition and asthenia in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1646-1649. doi: 10.3969/j.issn.1001-5256.2022.07.035
[6]	Chinese Society of Nutritional Oncology, Chinese Society for Parenteral and Enteral Nutrition. Expert opinion on nutritional treatment for patients with biliary tract tumors[J]. Journal of Clinical Hepatology, 2021, 37(9): 2058-2061. doi: 10.3969/j.issn.1001-5256.2021.09.011
[7]	Bo GAO, Yuzheng ZHUGE. Malnutrition in liver cirrhosis: Benefits from improving portal hypertension[J]. Journal of Clinical Hepatology, 2021, 37(12): 2767-2769. doi: 10.3969/j.issn.1001-5256.2021.12.005
[8]	Dandan JIA, Guiying ZHU, Shiyao LIAO, Hui ZHANG, Hui GUO, Lili YANG, Changmiao WANG. Interpretation of European Society for Clinical Nutrition and Metabolism practical guideline : Clinical nutrition in liver disease (2020)[J]. Journal of Clinical Hepatology, 2021, 37(7): 1553-1557. doi: 10.3969/j.issn.1001-5256.2021.07.015
[9]	Xiaoting SONG, Wentao XU, Yu CHEN, Xingshun QI. An excerpt of malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2021, 37(12): 2787-2789. doi: 10.3969/j.issn.1001-5256.2021.12.011
[10]	Huijuan XIAO, Tao HAN. Prevention and treatment of malnutrition, sarcopenia, and osteoporosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 26-30. doi: 10.3969/j.issn.1001-5256.2021.01.006
[11]	Xiao HuiJuan, Qi YuMei, Han Tao. An excerpt of ESPEN guideline on clinical nutrition in liver disease (2019)[J]. Journal of Clinical Hepatology, 2019, 35(5): 968-972. doi: 10.3969/j.issn.1001-5256.2019.05.007
[12]	Ma Bao, Deng Yong, Wang ZhiXin, Wang HaiJiu, Fan HaiNing. A preliminary study of the pathogenesis of malnutrition in patients with hepatic alveolar echinococcosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 204-206. doi: 10.3969/j.issn.1001-5256.2018.01.045
[13]	Zhu BingHua, Zhao ZhangQing, Zhou Yang, Xu LieMing. A nutritional risk screening model for patients with liver cirrhosis established using discriminant analysis[J]. Journal of Clinical Hepatology, 2017, 33(6): 1106-1111. doi: 10.3969/j.issn.1001-5256.2017.06.018
[14]	Zhu Bin, Zou CongCong, Zheng Xin. Malnutrition assessment and nutrition support therapy for end-stage liver disease[J]. Journal of Clinical Hepatology, 2017, 33(9): 1699-1706. doi: 10.3969/j.issn.1001-5256.2017.09.014
[15]	Gan XueMei, Li Wu. Nutrition support therapy for patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2016, 32(1): 178-181. doi: 10.3969/j.issn.1001-5256.2016.01.039
[16]	Zhang HuiKai, Meng XiangLin, Li HaiLei, Xu YuLing, Luo HongWei. Current status of malnutrition and its association with prognosis in hospitalized patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1100-1103. doi: 10.3969/j.issn.1001-5256.2016.06.015
[17]	Zhang Jian. Correlation between malnutrition and prognosis of hepatitis A in Uygur children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1235-1237. doi: 10.3969/j.issn.1001-5256.2015.08.013
[18]	Zhang Min, Hang Lei, Yuan XiaoJie, Yan HongQing. Observation of dietary intervention on nutritional risk in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(8): 764-767. doi: 10.3969/j.issn.1001-5256.2014.08.016
[19]	Wang MaoRong. Paying attention to nutritional management of hepatic encephalopathy in patients with liver cirrhosis: introduction to ISHEN consensus[J]. Journal of Clinical Hepatology, 2013, 29(9): 649-651. doi: 10.3969/j.issn.1001-5256.2013.09.004

Supplements(1)

Supplements

王晶-华东沿海地区多中心40例胰腺肿瘤患者基因组图谱分析-附录1.pdf

Cited By

Cited by

Periodical cited type(6)

1.	严兆兰. 青海地区乙型肝炎肝硬化并发轻微肝性脑病Stroop测试及诱发疾病危险因素调查分析. 中华养生保健. 2024(22): 84-86 .
2.	符健，高艺，林锋，李盼盼. 海口地区轻微肝性脑病PHES标准参考值范围的研究. 海南医学. 2023(13): 1903-1907 .
3.	樊亚楠，纪童童，梁荣月，于岩岩，徐京杭. 肝硬化合并显性肝性脑病危险因素的回顾性分析：一项单中心病例对照研究. 中华肝脏病杂志. 2021(02): 133-136 .
4.	边倩，解新科，寇小妮，李京涛，魏海梁，闫曙光. 通腑降浊汤联合乳果糖治疗热扰心神型肝性脑病临床观察. 山东中医杂志. 2021(06): 577-582 .
5.	覃秀容，陈月桥，石清兰，毛德文. 轻微肝性脑病的中西医研究进展. 中医药导报. 2020(12): 152-156 .
6.	王琳. 疏肝解郁胶囊治疗伴抑郁焦虑的肝性脑病患者的效果. 国际精神病学杂志. 2019(05): 925-928 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4)

Get Citation

PDF

XML

Article Metrics

Article views (669) PDF downloads(40)

Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases

DOI: 10.3969/j.issn.1001-5256.2022.02.028